Antibody responses to envelope glycoproteins in HIV-1 infection

Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups. Binding but non-neutralizing responses are directed to epitopes that are expressed on isolated envelope glycoproteins but not on the native envelope trimer found on the surface of virions and responsible for mediating the entry of virus into target cells. Strain-specific responses and broadly neutralizing responses, in contrast, target epitopes that are expressed on the native trimer, as revealed by recently resolved structures. The past few years have seen the isolation of many broadly neutralizing antibodies of remarkable potency that have shown prophylactic and therapeutic activities in animal models. These antibodies are helping to guide rational vaccine design and therapeutic strategies for HIV-1.

[1]  I. Wilson,et al.  Insights into the trimeric HIV-1 envelope glycoprotein structure. , 2015, Trends in biochemical sciences.

[2]  Y. Masuho,et al.  Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. , 1991, Virology.

[3]  Tongqing Zhou,et al.  Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.

[4]  Peter D. Kwong,et al.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site , 2005, The Journal of experimental medicine.

[5]  Antonio Lanzavecchia,et al.  Broadly neutralizing antiviral antibodies. , 2013, Annual review of immunology.

[6]  S. Gnanakaran,et al.  Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.

[7]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[8]  Young Do Kwon,et al.  Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.

[9]  D. Burton Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[10]  Gianguido C. Cianci,et al.  Human cervicovaginal mucus contains an activity that hinders HIV-1 movement , 2012, Mucosal Immunology.

[11]  J. Mascola,et al.  147 Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2011 .

[12]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[13]  S. Zolla-Pazner,et al.  Brief Definitive Report , 2022 .

[14]  Adam Godzik,et al.  A Blueprint for HIV Vaccine Discovery. , 2012, Cell host & microbe.

[15]  D. Burton,et al.  Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.

[16]  Gary J. Nabel,et al.  Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination , 2014, Science Translational Medicine.

[17]  T. Hope,et al.  Differential Binding of IgG and IgA to Mucus of the Female Reproductive Tract , 2013, PloS one.

[18]  J. Ravetch,et al.  FcγRs in health and disease. , 2011, Current topics in microbiology and immunology.

[19]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[20]  J. Margolick,et al.  HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. , 1996, Journal of immunology.

[21]  R. Doms,et al.  Dissecting the neutralizing antibody specificities of broadly neutralizing sera from 1 HIV-1 infected donors 2 * , 2007 .

[22]  L. M. Mansky,et al.  Activity of a Novel Combined Antiretroviral Therapy of Gemcitabine and Decitabine in a Mouse Model for HIV-1 , 2012, Antimicrobial Agents and Chemotherapy.

[23]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[24]  L. Morris,et al.  Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection , 2014, Current opinion in HIV and AIDS.

[25]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[26]  Lynn Morris,et al.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein , 2012, The Journal of experimental medicine.

[27]  D. Burton,et al.  Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.

[28]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[29]  Scott D Boyd,et al.  Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. , 2014, Cell host & microbe.

[30]  F. Bibollet-Ruche,et al.  Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.

[31]  J. Binley,et al.  Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected , 2011, Journal of Virology.

[32]  Feng Gao,et al.  Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals , 2011, Journal of Virology.

[33]  D. Forthal,et al.  Fc receptor-mediated antiviral antibodies , 2009, Current opinion in HIV and AIDS.

[34]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[35]  Han Gao,et al.  Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.

[36]  Florian Klein,et al.  Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy , 2014, Cell.

[37]  L. Morris,et al.  Virological features associated with the development of broadly neutralizing antibodies to HIV-1. , 2015, Trends in microbiology.

[38]  Daphne Koller,et al.  The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies , 2013, PLoS pathogens.

[39]  Tanmoy Bhattacharya,et al.  Role of donor genital tract HIV-1 diversity in the transmission bottleneck , 2011, Proceedings of the National Academy of Sciences.

[40]  D. Burton,et al.  Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo , 2012, Proceedings of the National Academy of Sciences.

[41]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[42]  John P. Moore,et al.  Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits , 2014, Retrovirology.

[43]  T. Kepler,et al.  Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design , 2012, Journal of Virology.

[44]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[45]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[46]  Tongqing Zhou,et al.  Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization , 2013, Cell.

[47]  James E. Crowe,et al.  Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes , 2012, PloS one.

[48]  T. Hope,et al.  New paradigms for functional HIV-specific nonneutralizing antibodies. , 2013, Current opinion in HIV and AIDS.

[49]  Ron Diskin,et al.  HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.

[50]  A MarioCalvo,et al.  Vaccination with ALVAC and AIDS-VAX to prevent HIV-1 infection in Thailand , 2010 .

[51]  M. Nussenzweig,et al.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.

[52]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[53]  J. Hoxie,et al.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.

[54]  D. Montefiori,et al.  Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.

[55]  Wayne C Koff,et al.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.

[56]  R. Haubrich,et al.  Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. , 1999, The Journal of infectious diseases.

[57]  C. Bailey-Kellogg,et al.  Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. , 2013, The Journal of clinical investigation.

[58]  John P. Moore,et al.  Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[59]  J. Sodroski,et al.  Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.

[60]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[61]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[62]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[63]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[64]  J. Kappes,et al.  High‐throughput quantitative analysis of HIV‐1 and SIV‐specific ADCC‐mediating antibody responses , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[65]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[66]  John R Mascola,et al.  Defining the protective antibody response for HIV-1. , 2003, Current molecular medicine.

[67]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[68]  Ryan McBride,et al.  Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.

[69]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[70]  Feng Gao,et al.  Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies , 2014, Cell.

[71]  Vicki C. Ashley,et al.  Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia , 2008, Journal of Virology.

[72]  N. Haigwood,et al.  Evaluation of Passively Transferred, Nonneutralizing Antibody-Dependent Cellular Cytotoxicity-Mediating IgG in Protection of Neonatal Rhesus Macaques against Oral SIVmac251 Challenge1 , 2006, The Journal of Immunology.

[73]  Yan Liu,et al.  Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 , 2013, Nature Structural &Molecular Biology.

[74]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[75]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[76]  Guido Ferrari,et al.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial. , 2012, The New England journal of medicine.

[77]  T. Greenough,et al.  A Novel Assay for Antibody-Dependent Cell-Mediated Cytotoxicity against HIV-1- or SIV-Infected Cells Reveals Incomplete Overlap with Antibodies Measured by Neutralization and Binding Assays , 2012, Journal of Virology.

[78]  Lynn Morris,et al.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.

[79]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[80]  Pascal Poignard,et al.  Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.

[81]  Lynn Morris,et al.  Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.

[82]  Guido Ferrari,et al.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. , 2013, Immunity.

[83]  R. Lerner Modern approaches to new vaccines including prevention of AIDS , 1989 .

[84]  J. Mascola,et al.  Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques , 2014, The Journal of experimental medicine.

[85]  John P. Moore,et al.  Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody , 2011, Proceedings of the National Academy of Sciences.

[86]  C. Barbas,et al.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[88]  Q. Sattentau,et al.  Comparative Efficiency of HIV-1-Infected T Cell Killing by NK Cells, Monocytes and Neutrophils , 2013, PloS one.

[89]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[90]  John P. Moore,et al.  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[91]  L. Morris,et al.  The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.

[92]  Michael S. Seaman,et al.  Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.

[93]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[94]  Douglas D. Richman,et al.  Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.

[95]  Gwo-Yu Chuang,et al.  Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface , 2014, Nature.

[96]  J. Kappes,et al.  Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4+ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding , 2012, Journal of Virology.

[97]  M. Nussenzweig,et al.  Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity , 2014, Cell.

[98]  G. Alter,et al.  Lack of Protection following Passive Transfer of Polyclonal Highly Functional Low-Dose Non-Neutralizing Antibodies , 2014, PloS one.

[99]  James C Paulson,et al.  Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. , 2014, Immunity.

[100]  John P. Moore,et al.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation , 2013, Proceedings of the National Academy of Sciences.

[101]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Tongqing Zhou,et al.  Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site , 2009, PLoS pathogens.

[103]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[104]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[105]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[106]  L. Stamatatos HIV vaccine design: the neutralizing antibody conundrum. , 2012, Current opinion in immunology.

[107]  J. Binley,et al.  Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[108]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[109]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[110]  M. Nussenzweig,et al.  A mouse model for HIV-1 entry , 2012, Proceedings of the National Academy of Sciences.

[111]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[112]  David C Montefiori,et al.  The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.